• Ginkgo Bioworks, Novo Nordisk Partnership, Mission Bio Updates Platform, PathAI, Google Cloud Team Up, More

    Bio-IT World | Ginkgo Bioworks has expanded its strategic partnership with Novo Nordisk; Mission Bio introduced sample multiplexing features for the company’s Tapestri Platform; PathAI announced a strategic partnership with Google Cloud at Bio-IT World Conference & Expo to help biopharma companies and anatomic pathology labs accelerate the adoption of AI and digital pathology; more.

    Apr 25, 2024

  • Follow the Money: Lymphatic System Platform, Endovascular Device System, Generative AI For Small Molecule Therapies, More

    Bio-IT World | Seaport Therapeutics plans to advance their Glyph platform, which leverages the lymphatic system to create new medicines building on clinically validated mechanisms and has demonstrated clinical proof-of-concept; Nectero Medical will accelerate the execution of the Phase II/III (stAAAble) trial and to support the submission of a New Drug Application with the U.S. Food and Drug Administration for the Nectero Endovascular Aneurysm Stabilization Treatment (Nectero EAST) System; DeepCure will further develop its generative AI and physics-based engine to innovate the discovery of small molecule therapies for challenging targets; more.

    Apr 24, 2024

  • AI Ushers in HPC Revival Says TACC’s Dan Stanzione

    Bio-IT World | High performance computing is enjoying an extreme vindication, said Dan Stanzione, Associate Vice President for Research at The University of Texas at Austin and Executive Director of TACC. In the opening plenary presentation at last week’s Bio-IT World Conference & Expo, Stanzione said that after years of cloud computing hype, artificial intelligence now demands traditional high performance computing architecture.

    Apr 23, 2024

  • Unlocking Targeted Cancer Care: Biomarkers as the Key to Personalized Treatments

    Bio-IT World | In modern medicine, biomarkers stand as pivotal indicators of biological processes or responses to therapeutic interventions, signaling a new era in clinical trial design and patient care. The driving idea behind the use of these tools is that by integrating the right biomarker information, scientists can properly select patients who are most likely to benefit from a particular therapy.

    Apr 19, 2024